---
schema_version: "secwatch.filing_event.v1"
accession: "0002019410-25-000026"
form_type: "8-K"
ticker: "CAI"
cik: "0002019410"
company_name: "Caris Life Sciences, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:26:00.327944+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Caris Life Sciences Q3 revenue $216.8M, up 113%, raises FY2025 guidance to $720-730M

## Summary
- Net income of $24.3M vs. loss of $67.7M YoY; diluted EPS $0.08 vs. ($2.59).
- Gross margin expanded to 68.0% from 43.7% YoY; clinical cases up 18.2% to 50,763.
- Positive Adjusted EBITDA of $51.2M and free cash flow of $55.3M.
- Full-year 2025 revenue guidance raised to $720-730M, representing 75-77% YoY growth.
- Molecular profiling services revenue grew 121.3% YoY to $207.6M.

## SEC filing metadata
- accession: 0002019410-25-000026
- form_type: 8-K
- ticker: CAI
- cik: 0002019410
- company_name: Caris Life Sciences, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2019410/000201941025000026/0002019410-25-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2019410/000201941025000026/cai-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002019410-25-000026
- JSON: https://secwatch.observer/filing/0002019410-25-000026.json
- Plain text: https://secwatch.observer/filing/0002019410-25-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.